Form 4: uniQure Director Reports Acquisition of Equity Awards

uniQure N.V. Director Madhavan Balachandran has reported the acquisition of 7,970 restricted share units and 15,630 stock options as part of his compensation.

Summary

• Madhavan Balachandran, a Director of uniQure N.V. (QURE), reported changes in his beneficial ownership of the company's securities via a Form 4 filing.
• On June 11, 2025, Mr. Balachandran acquired 7,970 Ordinary Shares in the form of Restricted Share Units (RSUs) at a price of $0 per share.
• These RSUs represent the contingent right to receive one Ordinary Share each and were granted under the Issuer's 2014 Share Incentive Plan, as amended and restated.
• The RSUs are scheduled to vest 100% on the first anniversary of the grant date (June 11, 2026), contingent on Mr. Balachandran's continued relationship with uniQure.
• Additionally, on June 11, 2025, Mr. Balachandran acquired 15,630 Stock Options with an exercise price of $16.22 per share.
• These stock options also vest 100% on the first anniversary of the grant date (June 11, 2026), subject to his continued relationship with the Issuer, and have an expiration date of June 11, 2035.
• Following these transactions, Mr. Balachandran beneficially owns 39,809 Ordinary Shares directly and 15,630 Stock Options directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is generally a positive sign of continued alignment and retention, but does not contain information that would significantly alter the company's financial outlook or operations. It's a neutral-to-slightly positive event.

Positives

• The grant of equity awards to Director Madhavan Balachandran aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company's success.
• The continued grant of equity compensation to a director indicates ongoing commitment and retention of key management personnel.

Future Outlook

The acquired Restricted Share Units and Stock Options are subject to a one-year vesting period, contingent on the reporting person's continued relationship with uniQure N.V. through June 11, 2026. The stock options have an expiration date of June 11, 2035.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry where equity compensation, such as restricted share units and stock options, is commonly used to incentivize and retain directors and key personnel, aligning their long-term interests with company performance and shareholder value.

Related Party Transactions

• The grant of Restricted Share Units and Stock Options to Director Madhavan Balachandran constitutes a related party transaction as it involves compensation provided by the issuer to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders by incentivizing long-term company performance and share price appreciation.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for broader employee incentive programs.

Next Steps

• The Restricted Share Units and Stock Options are expected to vest on June 11, 2026, subject to the director's continued service.
• The Stock Options will remain exercisable until their expiration date of June 11, 2035.

Key Dates

Keywords

uniQure N.V., QURE, SEC Form 4, Beneficial Ownership, Restricted Share Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Insider Transaction, Share Incentive Plan